"Concussion Pill" on the horizon as World Brain Day

A combination cannabidiol (CBD) and an anesthetic is promising to reduce post-traumatic brain cell inflammation, headaches, pain and other symptoms associated with concussed a pre pilot study. -clinical by researchers from the University of Miami in a combination of CBD (a cannabinoid derivative of hemp) with an NMDA antagonist (an anesthetic used in animals and humans) for the treatment of traumatic brain injury and a Concussion showed that combined therapy improved the cognitive functions of animals compared to those treated with a single vehicle, and no adverse effects were observed with combination therapy or with individual components. [19] 659003] Scythian Biosciences gave $ 16 million to Miller's Miamis School for the five-year study, researchers believing that the combination could reduce brain cell damage, headaches, pain and other symptoms associated with a concussion

The results of the study were published just days before World Brain Day, which was marked annually by the World Federation of Neurology (WFN). About 120 organizations around the world participate in this awareness initiative, which is devoted to a different topic each year. This year's theme is "Clean Air for Brain Health"; According to recent estimates, the annual number of deaths attributable to polluted air is 9 million worldwide.

Neurological Surgery Professor Gillian A. Hotz, principal investigator of the Miller study, said that more systematic research was needed to investigate the neuroprotective properties of CBD and improve treatment mild to moderate TBIs (She said the next phase of research would involve a small human pilot study, presumably administering the compounds in pill form to a control group and two groups of TBI, acute and chronic patients. Outcome domains – cognitive, behavioral, psychosocial, sleep, pain, sensorimotor, cardiovascular biomarkers, inflammatory and neuroimaging studies – to evaluate the effectiveness of the drug.After the study is completed, the data will be analyzed and all security issues will be addressed.

If the treatment is deemed safe and effective, the third phase Research will be starting a large-scale clinical trial over the next three years. With FDA surveillance, the data will reveal whether the compound is an effective therapeutic treatment for people suffering from different severities of TBI and concussion.

Traumatic brain injury is a leading cause of death and disability in the United States. According to the Centers for Disease Control and Prevention, each year about two million children and adolescents are affected. Most of these people face short-term effects like headaches and dizziness, while others run an increased risk of chronic long-term medical problems, including attention disorders. , memory, anxiety, depression and dementia. KiDZ Neuroscience Center at the Miami Project and at the Concussion Program of the Institute of Sports Medicine at the University of Miami. His team has developed a concussion protocol including education and training for doctors and coaches in an effort to provide a solution to the growing concern of managing concussions in sport. But one thing has escaped the team: "A clinically proven drug to treat concussion, whether or not this study results in a pill that can treat a concussion, this type of research will pave the way for the treatment of concussion. UM and other researchers to better manage concussions. "

Rendering